Literature DB >> 29035729

Pre-clinical in vitro infection models.

George L Drusano1.   

Abstract

Given the current magnitude of the problem of antimicrobial resistance, particularly in the hospital setting, getting new agents to patients at the right dose and schedule is incredibly important. In vitro systems such as the 1-compartment model and the hollow fiber infection model (HFIM) can provide valuable information that allows rational decisions to be made which will drive the best choices of dose and schedule. Studies identifying the dynamically-linked index (dose fractionation studies) and the size of the index to obtain a specific amount of bacterial kill can be performed in both systems. Studies to examine dosing regimens that will help suppress resistance emergence are best done in the HFIM.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2017        PMID: 29035729     DOI: 10.1016/j.coph.2017.09.011

Source DB:  PubMed          Journal:  Curr Opin Pharmacol        ISSN: 1471-4892            Impact factor:   5.547


  7 in total

1.  Optimal kinetic exposures for classic and candidate antitrypanosomals.

Authors:  Kirsten J Meyer; David J Meyers; Theresa A Shapiro
Journal:  J Antimicrob Chemother       Date:  2019-08-01       Impact factor: 5.790

Review 2.  World Health Organization Global Gonococcal Antimicrobial Surveillance Program (WHO GASP): review of new data and evidence to inform international collaborative actions and research efforts.

Authors:  Magnus Unemo; Monica M Lahra; Michelle Cole; Patricia Galarza; Francis Ndowa; Irene Martin; Jo-Anne R Dillon; Pilar Ramon-Pardo; Gail Bolan; Teodora Wi
Journal:  Sex Health       Date:  2019-09       Impact factor: 2.706

3.  Pharmacodynamic Evaluation of Zoliflodacin Treatment of Neisseria gonorrhoeae Strains With Amino Acid Substitutions in the Zoliflodacin Target GyrB Using a Dynamic Hollow Fiber Infection Model.

Authors:  Susanne Jacobsson; Daniel Golparian; Joakim Oxelbark; Francois Franceschi; David Brown; Arnold Louie; George Drusano; Magnus Unemo
Journal:  Front Pharmacol       Date:  2022-04-14       Impact factor: 5.988

Review 4.  When One Drug Is Not Enough: Context, Methodology, and Future Prospects in Antibacterial Synergy Testing.

Authors:  Thea Brennan-Krohn; James E Kirby
Journal:  Clin Lab Med       Date:  2019-06-12       Impact factor: 1.935

5.  Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against Neisseria gonorrhoeae in a Dynamic Hollow Fiber Infection Model.

Authors:  Susanne Jacobsson; Daniel Golparian; Joakim Oxelbark; Emilie Alirol; Francois Franceschi; Tomas N Gustafsson; David Brown; Arnold Louie; George Drusano; Magnus Unemo
Journal:  Front Pharmacol       Date:  2021-05-21       Impact factor: 5.810

Review 6.  The Role of PK/PD Analysis in the Development and Evaluation of Antimicrobials.

Authors:  Alicia Rodríguez-Gascón; María Ángeles Solinís; Arantxa Isla
Journal:  Pharmaceutics       Date:  2021-06-03       Impact factor: 6.321

7.  Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.

Authors:  Diane C Broussou; Marlène Z Lacroix; Pierre-Louis Toutain; Frédérique Woehrlé; Farid El Garch; Alain Bousquet-Melou; Aude A Ferran
Journal:  Front Microbiol       Date:  2018-03-27       Impact factor: 5.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.